HK2 and lung cancer: Hexokinase 2: HK2 is significantly overexpressed in treatment-resistant primary and metastatic breast cancer [37,38,39,40], bladder cancer [112], cervical squamous cell carcinoma [113], colorectal cancer [114], neuroendocrine tumor [103], ovarian epithelial tumors [104], glioblastoma [55,105], hepatocellular carcinoma [30], laryngeal squamous cell carcinoma [31], lung cancer [32], neuroblastoma [33], pancreatic cancer [34], and prostate cancer.